Johns Hopkins ABX Guide
Obiltoxaximab
INDICATIONS
FDA
FDA
- Treatment of inhalational anthrax due to Bacillus anthracis (in combination with antibacterial drugs)
- Prevention of inhalational anthrax when alternative agents are unavailable
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: June 1, 2016
Citation
Dzintars, Kathryn. "Obiltoxaximab." Johns Hopkins ABX Guide, The Johns Hopkins University, 2016. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540668/all/Obiltoxaximab.
Dzintars K. Obiltoxaximab. Johns Hopkins ABX Guide. The Johns Hopkins University; 2016. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540668/all/Obiltoxaximab. Accessed June 10, 2023.
Dzintars, K. (2016). Obiltoxaximab. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540668/all/Obiltoxaximab
Dzintars K. Obiltoxaximab [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2016. [cited 2023 June 10]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540668/all/Obiltoxaximab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Obiltoxaximab
ID - 540668
A1 - Dzintars,Kathryn,PharmD, BCPS
Y1 - 2016/06/01/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540668/all/Obiltoxaximab
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
